CO2021002087A2 - Método para tratar la epilepsia - Google Patents

Método para tratar la epilepsia

Info

Publication number
CO2021002087A2
CO2021002087A2 CONC2021/0002087A CO2021002087A CO2021002087A2 CO 2021002087 A2 CO2021002087 A2 CO 2021002087A2 CO 2021002087 A CO2021002087 A CO 2021002087A CO 2021002087 A2 CO2021002087 A2 CO 2021002087A2
Authority
CO
Colombia
Prior art keywords
fenfluramine
epileptic seizure
racemate
treatment
less
Prior art date
Application number
CONC2021/0002087A
Other languages
English (en)
Inventor
Jeffrey Paul Bechard
Robin Paul Sherrington
Jean-Jacques Alexandre Cadieux
Parisa Karimi Tari
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of CO2021002087A2 publication Critical patent/CO2021002087A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En determinadas modalidades, la presente descripción está dirigida a los métodos y los usos para tratar a un mamífero que tiene un trastorno convulsivo epiléptico o que está en riesgo de tener un trastorno convulsivo epiléptico, que comprenden la administración de determinados enantiómeros de la fenfluramina aislados descritos en la presente descripción que son sorprendentemente efectivos como fármacos antiepilépticos (AED), a pesar de tener menor potencia anticonvulsiva que el racemato de la fenfluramina, en virtud de que también es menos cardiotóxico que el racemato de la fenfluramina. Las modalidades preferidas contemplan el tratamiento del síndrome de Dravet; otras modalidades preferidas contemplan el tratamiento de otros trastornos convulsivos epilépticos.
CONC2021/0002087A 2018-07-27 2021-02-23 Método para tratar la epilepsia CO2021002087A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862711051P 2018-07-27 2018-07-27
PCT/US2019/043765 WO2020023923A1 (en) 2018-07-27 2019-07-26 Method for treating epilepsy

Publications (1)

Publication Number Publication Date
CO2021002087A2 true CO2021002087A2 (es) 2021-04-30

Family

ID=67551433

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0002087A CO2021002087A2 (es) 2018-07-27 2021-02-23 Método para tratar la epilepsia

Country Status (19)

Country Link
US (1) US20200030260A1 (es)
EP (1) EP3829558B1 (es)
JP (1) JP2021530541A (es)
KR (1) KR20210061332A (es)
CN (1) CN112930175A (es)
AU (1) AU2019310600A1 (es)
BR (1) BR112021001135A2 (es)
CA (1) CA3106031A1 (es)
CL (1) CL2021000196A1 (es)
CO (1) CO2021002087A2 (es)
CR (1) CR20210095A (es)
EA (1) EA202190369A1 (es)
IL (1) IL280128A (es)
MA (1) MA53329A (es)
MX (1) MX2021000987A (es)
PE (1) PE20211065A1 (es)
PH (1) PH12021550176A1 (es)
SG (1) SG11202100682YA (es)
WO (1) WO2020023923A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
LT3393655T (lt) 2015-12-22 2021-03-25 Zogenix International Limited Fenfluramino kompozicijos ir jų paruošimo būdai
EP3393470B1 (en) 2015-12-22 2021-01-20 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
US20180055789A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
EP3844158A1 (en) * 2018-08-31 2021-07-07 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
US11897995B2 (en) * 2019-07-18 2024-02-13 Basf Se Allophanate based dispersing agent
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20230078820A1 (en) * 2021-09-01 2023-03-16 Zogenix International Limited Fenfluramine for treatment of demyelinating diseases and conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104F (es) 1960-11-05
GB1175516A (en) 1966-04-15 1969-12-23 Science Union & Cie New Phenyl-Aminopropane Derivatives and Preparations Containing them
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
EP0762877B1 (en) * 1994-06-03 2001-03-21 THEJMDE Trust Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
JP2001524124A (ja) 1997-05-07 2001-11-27 ガレン（ケミカルズ）リミティド テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具
US6591909B1 (en) 2001-12-20 2003-07-15 Halliburton Energy Services, Inc. Whey protein retarder
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CA3204599A1 (en) * 2015-02-25 2016-09-01 The Regents Of The University Of California 5ht agonists for treating disorders
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
JP2017057188A (ja) * 2015-09-14 2017-03-23 ゾゲニクス インターナショナル リミテッド 特別な形態のてんかんの併用療法
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
MX2021000987A (es) 2021-06-15
SG11202100682YA (en) 2021-02-25
MA53329A (fr) 2022-03-02
PE20211065A1 (es) 2021-06-09
AU2019310600A1 (en) 2021-02-11
KR20210061332A (ko) 2021-05-27
CR20210095A (es) 2021-06-01
EP3829558B1 (en) 2024-07-03
JP2021530541A (ja) 2021-11-11
EP3829558C0 (en) 2024-07-03
CL2021000196A1 (es) 2021-12-31
EP3829558A1 (en) 2021-06-09
IL280128A (en) 2021-03-01
BR112021001135A2 (pt) 2021-04-20
PH12021550176A1 (en) 2021-10-11
WO2020023923A1 (en) 2020-01-30
EA202190369A1 (ru) 2021-06-10
CA3106031A1 (en) 2020-01-30
CN112930175A (zh) 2021-06-08
US20200030260A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CO2021002087A2 (es) Método para tratar la epilepsia
CL2015001700A1 (es) Tratamiento de trastornos del ritmo circadiano
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
CO2018004684A2 (es) Métodos para tratar la epilepsia
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
DOP2017000268A (es) Metodos y kits para tratar depresion
GT201500294A (es) Compuestos de biaril-amida como inhibidores de cinasa
BR112018004680A2 (pt) método de tratamento de distúrbios de desenvolvimento
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
EA202091057A3 (ru) Способы и композиции для лечения нарушений, ассоциированных со старением
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2011001714A1 (es) Compuestos derivados de bencenosulfonamidas, bloqueadores de canales de calcio; composicion farmaceutica que los comprende; uso en el tratamiento del dolor y enfermedades del snc.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
CL2019000190A1 (es) Tratamiento y prevención de los trastornos del sueño.
BR112022004272A2 (pt) Tratamento de prejuízo comportamental em encefalopatia epilética e desenvolvimental
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112016017886A2 (pt) grelina ou variantes ou derivados da mesma, e, método para tratamento de uma lesão cerebral leve em um indivíduo
BR112018005267A2 (pt) processo para realizar fototerapia ou fotoestimulação de retina, e sistema para realizar fototerapia ou fotoestimulação de retina
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
CO2023017973A2 (es) Trampas de ligando del factor de crecimiento transformante βeta para el tratamiento de enfermedades
BR112018016874A2 (pt) métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc)
AR126219A1 (es) TRAMPAS DE LIGANDOS DEL FACTOR DE CRECIMIENTO TRANSFORMADOR b PARA EL TRATAMIENTO DE ENFERMEDADES